Sun Pharma.Inds. (SUNPHARMA)

FairStock Score: 45/100 — MIXED

Score breakdown: P/E: 0/3 · ROCE: 1/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Investment Thesis

Sun Pharma is India's largest pharmaceutical company with strong global presence and decent revenue growth of 10%, but the current valuation at 34x PE appears stretched given declining profits of -4.51% YoY. The stock warrants caution as margin pressures and profit erosion need to stabilize before the premium valuation can be justified. Investors should wait for clearer signs of profitability recovery before initiating fresh positions.

Rating: HOLD (MEDIUM confidence) — 12M horizon

Strengths

• India's largest pharmaceutical company by market cap at Rs 4.17 lakh crore, providing unmatched scale, brand equity, and negotiating power across the value chain
• Strong ROCE of 20.21% demonstrates that despite profit pressures, the company is still generating good returns on the capital it has deployed — a sign of underlying business quality
• Diversified revenue mix across domestic branded generics, US specialty, emerging markets, and API segments provides resilience against sector-specific downturns
• Well-established specialty pipeline in dermatology, ophthalmology, and oncology positions the company for higher-margin revenue in coming years

Concerns

• Profit decline of -4.51% YoY despite 10% revenue growth is a serious red flag indicating significant margin erosion and operational inefficiency that needs urgent attention
• Expensive valuation at 34.34x PE is difficult to justify when earnings are contracting — historically, such a premium is warranted only for high-growth compounders, not profit-declining businesses
• Low dividend yield of 0.92% means shareholders are neither getting income returns nor capital appreciation assurance, making the risk-reward unattractive at current price levels
• Persistent US generics market headwinds could continue to weigh on consolidated profitability, delaying any meaningful earnings recovery and keeping the stock range-bound

AI Analysis

Here is what you need to know about Sun Pharma Industries. This is the biggest pharmaceutical company in India — we are talking about a market cap of over Rs 4 lakh crore, which is absolutely massive. The stock is trading at around Rs 1680 right now. So is it worth buying? Let me give you the honest picture. On the positive side, the company's sales are growing at a healthy 10% this year. That tells us the business is doing fine in terms of selling medicines — both in India and globally. Their ROCE, which measures how efficiently they use money to generate profits, is at 20.21%. That's actually quite good and shows the company knows how to deploy capital. Now here comes the problem. Even though sales are growing at 10%, profits have actually fallen by 4.51% this year. Think about it — selling more but earning less. That means somewhere, costs are rising faster than revenues. This margin compression is a serious concern and it directly impacts the stock's attractiveness. The valuation is another worry. At a PE ratio of 34 times, the market is pricing this stock as if it's a high-growth company. But when profits are declining, that kind of premium is hard to justify. You are paying a luxury price for a business going through some operational stress. The dividend yield is also just 0.92%, so you are not getting much income while you wait. My recommendation — if you already hold Sun Pharma, hold on. It is a quality franchise that will likely recover. But if you are looking to buy fresh, I would wait for 2-3 quarters to see if profit growth turns positive before committing new money. Patience is key here.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer